Falsely elevated thyroid hormone levels associated with fibrin interference in patients receiving oral anticoagulant therapy.

IF 2.1 4区 医学 Q3 MEDICAL LABORATORY TECHNOLOGY
Mitsuaki Tokumaru, Kenji Ohba, Yumiko Kashiwabara, Hiroyuki Takase, Chiga Hayashi, Takayuki Iwaki, Yasuhide Suzuki, Akio Matsushita, Shigekazu Sasaki, Takafumi Suda, Masato Maekawa
{"title":"Falsely elevated thyroid hormone levels associated with fibrin interference in patients receiving oral anticoagulant therapy.","authors":"Mitsuaki Tokumaru,&nbsp;Kenji Ohba,&nbsp;Yumiko Kashiwabara,&nbsp;Hiroyuki Takase,&nbsp;Chiga Hayashi,&nbsp;Takayuki Iwaki,&nbsp;Yasuhide Suzuki,&nbsp;Akio Matsushita,&nbsp;Shigekazu Sasaki,&nbsp;Takafumi Suda,&nbsp;Masato Maekawa","doi":"10.1177/00045632231159280","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Unique clinical courses were observed in two asymptomatic patients receiving warfarin who referred to our hospital because of suspected central hyperthyroidism. We eventually diagnosed these patients with falsely elevated thyroid hormone levels caused by macroscopically invisible fibrin. Although false results caused by fibrin interference in vitro have been identified in various immunoassays, especially in blood samples from patients receiving anticoagulant therapy, no studies on thyroid function testing have been reported. The experience in evaluating these cases prompted us to investigate the independent influence of oral anticoagulants via putative fibrin interference on thyroid function testing.</p><p><strong>Methods: </strong>We retrospectively reviewed known contributing factors that affect thyroid function testing including age, gender, medication history, body mass index, estimated glomerular filtration rate, smoking status, alcohol consumption, and the seasons of hospital visits from participants who presented the Department of Health Checkup between April 2010 and December 2020.</p><p><strong>Results: </strong>A propensity-matched analysis revealed that the median serum free thyroxine levels under oral anticoagulant were significantly higher (17.9 pmol/L, n = 60) than those without anticoagulants (16.0 pmol/L, n = 60; <i>p</i> < 0.001). It was noted that this difference was the largest among contributing factors we analyzed. No significant differences were noted in serum thyroid-stimulating hormone levels.</p><p><strong>Conclusions: </strong>We report two patients receiving warfarin with falsely elevated thyroid hormone levels caused by fibrin interference resembling central hyperthyroidism for the first time. Our retrospective study suggests that the medication status of oral anticoagulants should be considered when evaluating thyroid function tests.</p>","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":"60 4","pages":"249-258"},"PeriodicalIF":2.1000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00045632231159280","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: Unique clinical courses were observed in two asymptomatic patients receiving warfarin who referred to our hospital because of suspected central hyperthyroidism. We eventually diagnosed these patients with falsely elevated thyroid hormone levels caused by macroscopically invisible fibrin. Although false results caused by fibrin interference in vitro have been identified in various immunoassays, especially in blood samples from patients receiving anticoagulant therapy, no studies on thyroid function testing have been reported. The experience in evaluating these cases prompted us to investigate the independent influence of oral anticoagulants via putative fibrin interference on thyroid function testing.

Methods: We retrospectively reviewed known contributing factors that affect thyroid function testing including age, gender, medication history, body mass index, estimated glomerular filtration rate, smoking status, alcohol consumption, and the seasons of hospital visits from participants who presented the Department of Health Checkup between April 2010 and December 2020.

Results: A propensity-matched analysis revealed that the median serum free thyroxine levels under oral anticoagulant were significantly higher (17.9 pmol/L, n = 60) than those without anticoagulants (16.0 pmol/L, n = 60; p < 0.001). It was noted that this difference was the largest among contributing factors we analyzed. No significant differences were noted in serum thyroid-stimulating hormone levels.

Conclusions: We report two patients receiving warfarin with falsely elevated thyroid hormone levels caused by fibrin interference resembling central hyperthyroidism for the first time. Our retrospective study suggests that the medication status of oral anticoagulants should be considered when evaluating thyroid function tests.

在接受口服抗凝治疗的患者中,甲状腺激素水平错误升高与纤维蛋白干扰相关。
目的:观察两例因疑似中枢性甲状腺功能亢进而转诊至我院接受华法林治疗的无症状患者独特的临床过程。我们最终诊断这些患者是由肉眼看不见的纤维蛋白引起的甲状腺激素水平错误升高。尽管在各种免疫分析中,特别是在接受抗凝治疗的患者的血液样本中,已经发现了由体外纤维蛋白干扰引起的错误结果,但尚未有关于甲状腺功能测试的研究报道。评估这些病例的经验促使我们通过假定的纤维蛋白干扰来研究口服抗凝剂对甲状腺功能测试的独立影响。方法:我们回顾性回顾了影响甲状腺功能检测的已知因素,包括年龄、性别、用药史、体重指数、估计肾小球滤过率、吸烟状况、饮酒情况以及2010年4月至2020年12月期间在健康检查部门就诊的参与者的就诊季节。结果:倾向匹配分析显示,口服抗凝药物组血清游离甲状腺素水平中位数(17.9 pmol/L, n = 60)显著高于未使用抗凝药物组(16.0 pmol/L, n = 60;P < 0.001)。值得注意的是,这种差异在我们分析的影响因素中是最大的。血清促甲状腺激素水平无显著差异。结论:我们首次报道了两例接受华法林治疗的患者,由于纤维蛋白干扰导致甲状腺激素水平错误升高,类似于中枢性甲状腺功能亢进。我们的回顾性研究表明,在评估甲状腺功能检查时应考虑口服抗凝剂的用药状况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Clinical Biochemistry
Annals of Clinical Biochemistry Biochemistry, Genetics and Molecular Biology-Clinical Biochemistry
CiteScore
5.20
自引率
4.50%
发文量
61
期刊介绍: Annals of Clinical Biochemistry is the fully peer reviewed international journal of the Association for Clinical Biochemistry and Laboratory Medicine. Annals of Clinical Biochemistry accepts papers that contribute to knowledge in all fields of laboratory medicine, especially those pertaining to the understanding, diagnosis and treatment of human disease. It publishes papers on clinical biochemistry, clinical audit, metabolic medicine, immunology, genetics, biotechnology, haematology, microbiology, computing and management where they have both biochemical and clinical relevance. Papers describing evaluation or implementation of commercial reagent kits or the performance of new analysers require substantial original information. Unless of exceptional interest and novelty, studies dealing with the redox status in various diseases are not generally considered within the journal''s scope. Studies documenting the association of single nucleotide polymorphisms (SNPs) with particular phenotypes will not normally be considered, given the greater strength of genome wide association studies (GWAS). Research undertaken in non-human animals will not be considered for publication in the Annals. Annals of Clinical Biochemistry is also the official journal of NVKC (de Nederlandse Vereniging voor Klinische Chemie) and JSCC (Japan Society of Clinical Chemistry).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信